Merry Life Biomedical
Tainan City, Taiwan· Est.
Taiwan biotech MLBio develops autolysosome‑targeted therapeutics, with TML‑6 advancing to global Phase II for Alzheimer’s disease.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan biotech MLBio develops autolysosome‑targeted therapeutics, with TML‑6 advancing to global Phase II for Alzheimer’s disease.
NeurologyNeurodegenerative Diseases
Technology Platform
Proprietary small‑molecule platform that enhances autolysosome flux to clear pathogenic protein aggregates in neurodegenerative diseases.
Opportunities
Successful Phase II results could unlock licensing deals with major pharma and provide a novel disease‑modifying therapy for a large, growing AD market.
Risk Factors
Scientific uncertainty around autolysosome targeting, limited financial runway, and competition from established amyloid and tau therapeutics.
Competitive Landscape
MLBio competes with large biotech/pharma firms developing AD therapies, but differentiates through its autolysosome mechanism and oral small‑molecule format.